Mammary Cell News 10.22 June 7, 2018 | |
| |
TOP STORYHeterochromatin-Encoded Satellite RNAs Induce Breast Cancer Scientists provide evidence that increased levels of satellite RNAs in mammary glands induce tumor formation in mice. Using mass spectrometry, they showed that genomic instability induced by satellite RNAs occurs through interactions with BRCA1-associated protein networks required for the stabilization of DNA replication forks. [Mol Cell] Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)PHIP as a Therapeutic Target for Driver-Negative Subtypes of Melanoma, Breast, and Lung Cancer Investigators showed that pleckstrin homology domain-interacting protein (PHIP) promotes the progression of these “driver-negative” tumors. Suppression of PHIP expression significantly inhibited both tumor cell proliferation and invasion, coordinately suppressing phosphorylated AKT, cyclin D1, and talin1 expression in all three tumor types. [Proc Natl Acad Sci USA] Abstract The authors profiled a panel of thirty breast cancer cell lines in the absence of drugs for their mutations, copy number aberrations, mRNA and protein expression and protein phosphorylation, and for response to seven different kinase inhibitors. They then constructed a knowledge-based, Bayesian computational model that integrates these data types and estimates the relative contribution of various drug sensitivity mechanisms. [Cancer Res] Abstract Researchers showed that ionizing irradiation-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3) at the Tyr705 residue and the induction of ROS in wild-type and radioresistant MDA-MB-231 and MDA-MB-468 triple-negative breast cancer cell lines. [Oncogene] Abstract By constructing STARD13-correlated ceRNA 3′UTR stable overexpression or knockdown breast cancer cells, investigators explored the effects of STARD13-correlated ceRNA network on breast cancer stemness in vitro and in vivo. [J Hematol Oncol] Full Article To figure out the role of the architecture and composition of 3D cancer models on their tumor-mimicking capability, scientists studied the efficacy of doxorubicin, a well-known anticancer molecule in two different 3D cancer models: 3D breast cancer microtissue versus the golden standard represented by spheroid model. [Acta Biomater] Abstract | Graphical Abstract Investigators demonstrated that the stimulation of apoptosis by the binding of secreted acetylated-apurinic apyrimidinic endonuclease 1/redox factor-1 (APE1/Ref-1) to the receptor for advanced glycation end products was essential for triple-negative breast cancer cell death in response to hyperacetylation. [Sci Rep] Full Article PTBP1 Promotes the Growth of Breast Cancer Cells through the PTEN/Akt Pathway and Autophagy The authors investigated some roles of polypyrimidine tract binding protein 1 (PTBP1) in human breast cancer. They found that PTBP1 was upregulated in breast cancer tissues compared with normal tissues and the same result was confirmed in breast cancer cell lines. [J Cell Physiol] Abstract | Full Article Scientists showed that butyl benzyl phthalate induced proliferation of both ER+ MCF-7 and ER– MDA-MB-231 breast cancer cells, proved by increased cell viability, transition of cell cycle from G1 to S phase, upregulation of PCNA and Cyclin D1, and downregulation of p21. [Toxicol Lett] Abstract Researchers report that MRTF-A, a co-activator of SRF, is important for the regulation of type I collagen gene COL1A1 in breast cancer cells. [Biomed Pharmacother] Abstract | Graphical Abstract Investigators identified a novel circular RNA hsa_circ_0008039 with upregulated expression level in breast cancer tissues. By functional experiments, they found that hsa_circ_0008039 depletion significantly suppressed the proliferation, arrested cell-cycle progression and reduced migration in breast cancer. [Biochem Biophys Res Commun] Abstract | |
| |
REVIEWSBasal-Like Breast Cancers: From Pathology to Biology and Back Again Elucidating the mechanisms responsible for the profiles of basal-like tumors is an active area of investigation. More refined molecular analysis of patients’ samples and genetic strategies to produce breast cancers de novo from defined populations of normal mouse mammary cells have served as complementary approaches to identify relevant pathway alterations. [Stem Cell Reports] Full Article Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSPuma Biotechnology, Inc. announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 given in combination with the antibody drug conjugate T-DM1 were presented. [Press release from Puma Biotechnology, Inc. discussing research presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release Daiichi Sankyo Company, Limited announced that long-term Phase I safety and efficacy data for DS-8201, an investigational HER2-targeting antibody drug conjugate, in 241 heavily pretreated patients with HER2-expressing breast, gastric and other solid cancers who received recommended expansion doses of 5.4 mg/kg or 6.4 mg/kg, will be presented. [Press release from Daiichi Sankyo Company, Limited discussing research presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release | |
| |
INDUSTRY NEWSNovartis announced positive results from the third Phase III trial of Kisqali® in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant significantly prolonged progression-free survival (PFS) compared to fulvestrant alone in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2–) advanced breast cancer. [Novartis AG] Press Release Pfizer Inc. announced that the FDA accepted for filing and granted Priority Review designation to the company’s New Drug Application for talazoparib. The submission is based on results from the EMBRACA trial, which evaluated talazoparib versus chemotherapy in patients with germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. [Pfizer Inc.] Press Release Immunomedics, Inc. announced results from a Phase I/II study of its lead investigational antibody-drug conjugate, sacituzumab govitecan, in advanced stage estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. [Immunomedics, Inc.] Press Release SELLAS Life Sciences Group Inc. announced that the sponsor-principal investigator, after taking into account that key clinical development objectives were met as well as other regulatory considerations, and in agreement with SELLAS, determined to terminate early the Phase IIb independent investigator-sponsored clinical trial of trastuzumab +/- nelipepimut-S in HER2 1+/2+ breast cancer patients. [SELLAS Life Sciences Group Inc.] Press Release | |
| |
POLICY NEWSGo for Launch: A Former Astronaut Becomes Spain’s Science Minister Spain has a ministry of science again—and none other than the first Spanish astronaut is leading it. The new transition government led by socialist Pedro Sánchez announced that Pedro Duque, who visited space twice, will be at the helm of the newly created Ministry for Science, Innovation, and Universities. The announcement was cheered by the Spanish scientific community, which has long suffered from declining budgets and bureaucratic hurdles. [ScienceInsider] Editorial Scientists Fare Poorly in Super Tuesday Primary Vote Science-minded candidates seeking seats in the next U.S. Congress took a drubbing from their Democratic opponents in a raft of primary elections across the country. [ScienceInsider] Editorial Chile, Keen to Become a Knowledge Society, Creates a Ministry of Science Scientists in Chile have welcomed a decision by Congress to create a science ministry. Many researchers hope that a dedicated ministry will give science more prominence and better-coordinated policies—provided the ministry’s budget matches the government’s ambitions to “bring Chile towards an information and knowledge society,” as Gonzalo Blumel, the country’s minister secretary-general of the presidency, put it in a statement issued after the 31 May vote. [ScienceInsider] Editorial
| |
EVENTSNEW 6th Annual Metastatic Breast Cancer Conference Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral Research Associate – Breast Cancer (Howard University) Cancer Scientists – Breast Cancer Research (Qatar Biomedical Research Institute) Postdoctoral Position – Ovarian and Breast Cancer Research (Indiana University School of Medicine) Postdoctoral Position – Breast Cancer Research (Northwestern University) Postdoctoral Posion – Basic & Translational Breast Cancer Research (Northwestern University) Postdoctoral Position – Breast Cancer Research (Rutgers Cancer Institute of New Jersey) Graduate Student – Breast and Colorectal Cancer (Dalhousie University) Postdoctoral Fellows – Breast Cancer Stem Cell Research (New York University School of Medicine) Postdoctoral Fellowship – Cancer Research (Mass General Hospital/Harvard Medical School) Postdoctoral Fellow – Breast Cancer Research (Northwestern University) Postdoctoral Researcher – Breast Cancer (Baylor College of Medicine) Senior Research Technician – Breast Cancer (Baylor College of Medicine) Research Technician – Breast Cancer (Baylor College of Medicine) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|